Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Current Assets (2019 - 2025)

Historic Current Assets for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to $1.3 billion.

  • Madrigal Pharmaceuticals' Current Assets rose 2660.74% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 2660.74%. This contributed to the annual value of $1.0 billion for FY2024, which is 6208.34% up from last year.
  • According to the latest figures from Q3 2025, Madrigal Pharmaceuticals' Current Assets is $1.3 billion, which was up 2660.74% from $1.0 billion recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' Current Assets registered a high of $1.3 billion during Q3 2025, and its lowest value of $157.1 million during Q3 2022.
  • Its 5-year average for Current Assets is $593.1 million, with a median of $331.3 million in 2023.
  • Its Current Assets has fluctuated over the past 5 years, first tumbled by 4814.03% in 2022, then soared by 35172.23% in 2024.
  • Quarter analysis of 5 years shows Madrigal Pharmaceuticals' Current Assets stood at $271.7 million in 2021, then soared by 33.01% to $361.4 million in 2022, then soared by 76.35% to $637.3 million in 2023, then soared by 62.08% to $1.0 billion in 2024, then skyrocketed by 30.38% to $1.3 billion in 2025.
  • Its last three reported values are $1.3 billion in Q3 2025, $1.0 billion for Q2 2025, and $988.0 million during Q1 2025.